Type 1 diabetes alters ischemia-induced gene expression

Rahul Peravali, Lucas Gunnels, Satyanarayana Alleboina, Ivan Gerling, Ayotunde Dokun

Research output: Contribution to journalArticle

Abstract

Peripheral Artery Disease (PAD) is a chronic, activity-limiting disease that is caused by atherosclerotic occlusion of blood vessels outside the heart. Type 1 Diabetes (T1D) not only increases an individual's likelihood of developing PAD, but also contributes to poor clinical outcomes after PAD manifestation. Although there is some evidence suggesting that hyperglycemia might alter expression of genes involved in regulating PAD severity or outcomes, our knowledge about the specific genes and pathways involved remains incomplete. We induced experimental PAD or hind limb ischemia in T1D and non-diabetic mice and subjected the ischemic gastrocnemius muscle tissues to genome-wide mRNA transcriptome and pathway analysis. We identified 513 probe sets that represented 443 different genes with highly significant expression differences (p < 0.005) between the ischemic diabetic and ischemic non-diabetic muscle tissues. Moreover, pathway analysis of the differentially expressed genes identified pathways involved in essential biological processes such as “cell cycle,” “DNA replication,” “metabolic pathways,” “focal adhesion,” “regulation of actin cytoskeleton,” and “nucleotide excision repair”. Taken together, our data offer the opportunity to test hypotheses on the roles played by the altered genes/molecular pathways in poor PAD outcomes in diabetes. Such studies may lead to the development of specific therapies to improve PAD outcomes in patients with comorbid diabetes.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalJournal of Clinical and Translational Endocrinology
Volume15
DOIs
StatePublished - Mar 1 2019

Fingerprint

Peripheral Arterial Disease
Type 1 Diabetes Mellitus
Ischemia
Gene Expression
Genes
Biological Phenomena
Muscles
Focal Adhesions
Gene Expression Profiling
Metabolic Networks and Pathways
DNA Replication
Actin Cytoskeleton
DNA Repair
Hyperglycemia
Blood Vessels
Cell Cycle
Skeletal Muscle
Extremities
Genome
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Type 1 diabetes alters ischemia-induced gene expression. / Peravali, Rahul; Gunnels, Lucas; Alleboina, Satyanarayana; Gerling, Ivan; Dokun, Ayotunde.

In: Journal of Clinical and Translational Endocrinology, Vol. 15, 01.03.2019, p. 19-24.

Research output: Contribution to journalArticle

Peravali, Rahul ; Gunnels, Lucas ; Alleboina, Satyanarayana ; Gerling, Ivan ; Dokun, Ayotunde. / Type 1 diabetes alters ischemia-induced gene expression. In: Journal of Clinical and Translational Endocrinology. 2019 ; Vol. 15. pp. 19-24.
@article{90afa71872f842fcae97460b5b7856c0,
title = "Type 1 diabetes alters ischemia-induced gene expression",
abstract = "Peripheral Artery Disease (PAD) is a chronic, activity-limiting disease that is caused by atherosclerotic occlusion of blood vessels outside the heart. Type 1 Diabetes (T1D) not only increases an individual's likelihood of developing PAD, but also contributes to poor clinical outcomes after PAD manifestation. Although there is some evidence suggesting that hyperglycemia might alter expression of genes involved in regulating PAD severity or outcomes, our knowledge about the specific genes and pathways involved remains incomplete. We induced experimental PAD or hind limb ischemia in T1D and non-diabetic mice and subjected the ischemic gastrocnemius muscle tissues to genome-wide mRNA transcriptome and pathway analysis. We identified 513 probe sets that represented 443 different genes with highly significant expression differences (p < 0.005) between the ischemic diabetic and ischemic non-diabetic muscle tissues. Moreover, pathway analysis of the differentially expressed genes identified pathways involved in essential biological processes such as “cell cycle,” “DNA replication,” “metabolic pathways,” “focal adhesion,” “regulation of actin cytoskeleton,” and “nucleotide excision repair”. Taken together, our data offer the opportunity to test hypotheses on the roles played by the altered genes/molecular pathways in poor PAD outcomes in diabetes. Such studies may lead to the development of specific therapies to improve PAD outcomes in patients with comorbid diabetes.",
author = "Rahul Peravali and Lucas Gunnels and Satyanarayana Alleboina and Ivan Gerling and Ayotunde Dokun",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.jcte.2018.11.003",
language = "English (US)",
volume = "15",
pages = "19--24",
journal = "Journal of Clinical and Translational Endocrinology",
issn = "2214-6237",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Type 1 diabetes alters ischemia-induced gene expression

AU - Peravali, Rahul

AU - Gunnels, Lucas

AU - Alleboina, Satyanarayana

AU - Gerling, Ivan

AU - Dokun, Ayotunde

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Peripheral Artery Disease (PAD) is a chronic, activity-limiting disease that is caused by atherosclerotic occlusion of blood vessels outside the heart. Type 1 Diabetes (T1D) not only increases an individual's likelihood of developing PAD, but also contributes to poor clinical outcomes after PAD manifestation. Although there is some evidence suggesting that hyperglycemia might alter expression of genes involved in regulating PAD severity or outcomes, our knowledge about the specific genes and pathways involved remains incomplete. We induced experimental PAD or hind limb ischemia in T1D and non-diabetic mice and subjected the ischemic gastrocnemius muscle tissues to genome-wide mRNA transcriptome and pathway analysis. We identified 513 probe sets that represented 443 different genes with highly significant expression differences (p < 0.005) between the ischemic diabetic and ischemic non-diabetic muscle tissues. Moreover, pathway analysis of the differentially expressed genes identified pathways involved in essential biological processes such as “cell cycle,” “DNA replication,” “metabolic pathways,” “focal adhesion,” “regulation of actin cytoskeleton,” and “nucleotide excision repair”. Taken together, our data offer the opportunity to test hypotheses on the roles played by the altered genes/molecular pathways in poor PAD outcomes in diabetes. Such studies may lead to the development of specific therapies to improve PAD outcomes in patients with comorbid diabetes.

AB - Peripheral Artery Disease (PAD) is a chronic, activity-limiting disease that is caused by atherosclerotic occlusion of blood vessels outside the heart. Type 1 Diabetes (T1D) not only increases an individual's likelihood of developing PAD, but also contributes to poor clinical outcomes after PAD manifestation. Although there is some evidence suggesting that hyperglycemia might alter expression of genes involved in regulating PAD severity or outcomes, our knowledge about the specific genes and pathways involved remains incomplete. We induced experimental PAD or hind limb ischemia in T1D and non-diabetic mice and subjected the ischemic gastrocnemius muscle tissues to genome-wide mRNA transcriptome and pathway analysis. We identified 513 probe sets that represented 443 different genes with highly significant expression differences (p < 0.005) between the ischemic diabetic and ischemic non-diabetic muscle tissues. Moreover, pathway analysis of the differentially expressed genes identified pathways involved in essential biological processes such as “cell cycle,” “DNA replication,” “metabolic pathways,” “focal adhesion,” “regulation of actin cytoskeleton,” and “nucleotide excision repair”. Taken together, our data offer the opportunity to test hypotheses on the roles played by the altered genes/molecular pathways in poor PAD outcomes in diabetes. Such studies may lead to the development of specific therapies to improve PAD outcomes in patients with comorbid diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85057490185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057490185&partnerID=8YFLogxK

U2 - 10.1016/j.jcte.2018.11.003

DO - 10.1016/j.jcte.2018.11.003

M3 - Article

VL - 15

SP - 19

EP - 24

JO - Journal of Clinical and Translational Endocrinology

JF - Journal of Clinical and Translational Endocrinology

SN - 2214-6237

ER -